{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:08:35Z","timestamp":1792066115253,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111219","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:50:18Z","timestamp":1761299418000},"page":"111219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stereotactic ablative body radiotherapy for PSMA-PET\/CT staged, oligometastatic prostate cancer \u2013 A multi-centre study"],"prefix":"10.1016","volume":"214","author":[{"given":"Isabelle","family":"Schupak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-3746","authenticated-orcid":false,"given":"Michael","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Guerrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-4220","authenticated-orcid":false,"given":"Huong","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-5164","authenticated-orcid":false,"given":"Cristian","family":"Udovicich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Starmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Foroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl Lim","family":"Joon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.radonc.2025.111219_b0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13014-021-01776-8","article-title":"Radiotherapy of oligometastatic prostate cancer: a systematic review","volume":"16","author":"Rogowski","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111219_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2025.111219_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/cancers16030507","article-title":"Progress in oligometastatic prostate cancer: emerging imaging innovations and therapeutic approaches","volume":"16","author":"Oka","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2025.111219_b0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0030","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2025.111219_b0035","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur Urol"},{"issue":"1116","key":"10.1016\/j.radonc.2025.111219_b0040","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200496","article-title":"Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence","volume":"93","author":"Yan","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.111219_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00101","article-title":"SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer","volume":"5","author":"Azzam","year":"2015","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2025.111219_b0060","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/cancers14092073","article-title":"Local control after locally ablative, image-guided radiotherapy of oligometastases identified by gallium-68-PSMA-positron emission tomography in castration-sensitive prostate cancer patients (OLI-P)","volume":"14","author":"H\u00f6lscher","year":"2022","journal-title":"Cancers"},{"issue":"6_suppl","key":"10.1016\/j.radonc.2025.111219_b0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2025.111219_b0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2025.111219_b0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0085","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1471-2407-12-305","article-title":"Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial","volume":"12","author":"Palma","year":"2012","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.radonc.2025.111219_b0090","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.prro.2024.04.022","article-title":"A phase II trial of stereotactic body radiation therapy and androgen deprivation for oligometastases in prostate cancer (SBRT-SG 05)","volume":"14","author":"Conde-Moreno","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2025.111219_b0095","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2019.08.041","article-title":"Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the SABR-COMET randomized trial","volume":"105","author":"Olson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.radonc.2025.111219_b0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.eururo.2019.02.026","article-title":"Patient-reported quality of life following stereotactic body radiotherapy and conventionally fractionated external beam radiotherapy compared with active surveillance among men with localized prostate cancer","volume":"76","author":"Moon","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.radonc.2025.111219_b0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clon.2023.11.041","article-title":"Prospective longitudinal assessment of quality of life after stereotactic ablative radiotherapy for oligometastases: analysis of the population-based SABR-5 phase II trial","volume":"36","author":"Cruz-Lim","year":"2024","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111219_b0110","article-title":"Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort","volume":"45","author":"Bultijnck","year":"2024","journal-title":"Clin Transl Rad Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111219_b0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.radonc.2025.111219_b0120","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111219_b0125","unstructured":"Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05209243."},{"key":"10.1016\/j.radonc.2025.111219_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.euros.2024.11.008","article-title":"High detection rates for prostate-specific membrane antigen\u2013avid prostate cancer recurrence at low prostate-specific antigen levels on extended axial field-of-view positron emission tomography\/computed tomography","volume":"71","author":"Thomas","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.radonc.2025.111219_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110618","article-title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer","volume":"202","author":"Wang","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:26:39Z","timestamp":1786537599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"alternative-id":["S0167814025052235"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111219","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic ablative body radiotherapy for PSMA-PET\/CT staged, oligometastatic prostate cancer \u2013 A multi-centre study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111219"}}